Collegium Pharmaceutical(NASDAQ) COLL

Collegium Pharmaceutical helps people manage chronic pain and ADHD symptoms with specialized prescription drugs. It makes treatments that release medicine slowly over time or include features to discourage improper use. These products serve patients who require long-term care for severe medical conditions.

Managing Pain and ADHD

• ADHD Treatments: Stimulant medications like Jornay PM and Azstarys help patients six years of age and older manage attention deficit hyperactivity disorder.
• Chronic Pain Management: Branded products including Xtampza ER, Nucynta, and Belbuca provide relief for severe pain requiring continuous, long-term opioid therapy.
• Abuse-Deterrent Technology: Formulations like Xtampza ER are specifically engineered to deter common methods of drug abuse.
• Opioid-Induced Constipation: Symproic is an oral tablet used to treat bowel issues specifically caused by the long-term use of opioid pain medicines.
• Authorized Generics: Partnerships with third parties provide generic versions of Nucynta to broaden patient access and manage product life cycles.

Strategic Moves and New Additions

• Acquired Azstarys in May 2026 to expand the company's footprint in the market for ADHD treatments.
• Purchased Ironshore Therapeutics in 2024, adding the evening-dosed ADHD stimulant Jornay PM to its commercial lineup.
• Acquired BioDelivery Sciences International in March 2022, which added Belbuca and Symproic to the product portfolio.
• Launched authorized generic versions of Nucynta IR and Nucynta ER in early 2026 through a commercial agreement with Hikma.

What Makes the Portfolio Different?

Collegium focuses on differentiated drug delivery, such as evening dosing for ADHD and specialized buccal films that stick to the cheek for pain relief. The company manages a complex portfolio that balances high-margin branded treatments with authorized generic versions to navigate patent expirations and market competition.

A Look at the Financials

• Net product revenues reached $199.9 million in the three months ended June 30, 2026, up $11.9 million year over year.
• Net loss was $15.1 million in the second quarter of 2026, compared to a net income of $12.0 million in the 2025 quarter.
• Adjusted EBITDA, a non-GAAP measure, was $113.8 million for the three months ended June 30, 2026, up from $105.1 million in the 2025 period.
• Total net product revenues for the first six months of 2026 were $393.4 million.
• Cash and cash equivalents stood at $129.5 million as of June 30, 2026.

The Bigger Picture

Collegium has evolved from a pain-management specialist into a broader biopharmaceutical company with a significant presence in the ADHD market. By acquiring new therapies and managing drug lifecycles, the company maintains a diverse revenue stream across multiple medical conditions.